FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953184800> ?p ?o ?g. }

• W2953184800 endingPage "730" @default.
• W2953184800 startingPage "730" @default.
• W2953184800 abstract "Background: Venous thromboembolism (VTE) is an important clinical concern in children with or without cancer. Experience with dalteparin, a low molecular weight heparin, in the treatment of VTE in adults with cancer has been extensively published, but data in children are limited. Aims: We sought to determine the twice-daily dalteparin dose required to achieve target Anti-Xa levels of 0.5–1.0 IU/mL, as well as its pharmacodynamics (PD), efficacy, and safety in the treatment of VTE in children <19 years old, with or without cancer. Methods: This prospective, multi-center, Phase 2, open-label study consisted of 3 phases: 1) Dose Adjustment Phase of up to 7 days, in which Anti-Xa levels were measured following the first, second or third dose of dalteparin, until achievement of the target level; 2) PD Phase of up to 7 days, to obtain 2 randomized PD plasma samples for Anti-Xa determination; and 3) Follow-Up Phase, to complete up to 90 days of anticoagulant therapy. Patients were assessed for symptomatic new or progressive (i.e., recurrent) VTE as well as clinically relevant bleeding during treatment. Surveillance VTE imaging was performed at 90 ± 14 days. Results: The safety population consisted of 38 patients who received at least 1 dose of dalteparin (<2 years: n = 3; ≥2 to <8 years: n = 8; ≥8 to <12 years, n = 7; ≥12 to <19 years: n = 20). Twenty-six patients (68%) had a diagnosis of cancer at baseline, of which 23 (88%) were haematological malignancies. The median [range] dalteparin dose required to achieve target Anti-Xa levels decreased with age (<2 years: 207.5 IU/kg [201.5–213.5 IU/kg]; ≥2 to <8 years: 128.15 IU/kg [123.9–180.3 IU/kg]; ≥8 to <12 years: 125 IU/kg [124.5–152.6 IU/kg]; ≥12 to <19 years: 116.7 IU/kg [99.1–159 IU/kg]) (Figure). Therapeutic Anti-Xa levels were achieved in 90% of patients within a mean (SD) of 2.6 days (1.54 days); the mean (SD) number of dose adjustments per patient was 0.7 (0.98). One patient (3%) developed symptomatic recurrent VTE. No patients reported clinically-relevant bleeding. Four patients (11%) had treatment-related serious adverse events. 62% of patients had complete resolution of their VTE at the end of the 90-day reporting period.Summary/Conclusion: Twice-daily dalteparin dosing achieved therapeutic levels in 90% of children with or without cancer, with a satisfactory tolerability profile. The median therapeutic doses of dalteparin were higher for the two youngest age cohort groups (<2 years and 2 to <8 years). NCT00952380 Sources of Research Support: This study was sponsored by Pfizer Ltd." @default.
• W2953184800 created "2019-06-27" @default.
• W2953184800 creator A5008481962 @default.
• W2953184800 creator A5021997989 @default.
• W2953184800 creator A5052478814 @default.
• W2953184800 creator A5057343846 @default.
• W2953184800 creator A5061175897 @default.
• W2953184800 creator A5083214889 @default.
• W2953184800 creator A5086858573 @default.
• W2953184800 creator A5088928765 @default.
• W2953184800 date "2019-06-01" @default.
• W2953184800 modified "2023-09-26" @default.
• W2953184800 title "PS1584 A PHASE II DOSE-FINDING STUDY OF DALTEPARIN IN CHILDREN WITH VTE WITH OR WITHOUT CANCER" @default.
• W2953184800 doi "https://doi.org/10.1097/01.hs9.0000564584.17644.f8" @default.
• W2953184800 hasPublicationYear "2019" @default.
• W2953184800 type Work @default.
• W2953184800 sameAs 2953184800 @default.
• W2953184800 citedByCount "1" @default.
• W2953184800 countsByYear W29531848002021 @default.
• W2953184800 crossrefType "journal-article" @default.
• W2953184800 hasAuthorship W2953184800A5008481962 @default.
• W2953184800 hasAuthorship W2953184800A5021997989 @default.
• W2953184800 hasAuthorship W2953184800A5052478814 @default.
• W2953184800 hasAuthorship W2953184800A5057343846 @default.
• W2953184800 hasAuthorship W2953184800A5061175897 @default.
• W2953184800 hasAuthorship W2953184800A5083214889 @default.
• W2953184800 hasAuthorship W2953184800A5086858573 @default.
• W2953184800 hasAuthorship W2953184800A5088928765 @default.
• W2953184800 hasBestOaLocation W29531848001 @default.
• W2953184800 hasConcept C111113717 @default.
• W2953184800 hasConcept C112705442 @default.
• W2953184800 hasConcept C121608353 @default.
• W2953184800 hasConcept C126322002 @default.
• W2953184800 hasConcept C141071460 @default.
• W2953184800 hasConcept C187212893 @default.
• W2953184800 hasConcept C2776884760 @default.
• W2953184800 hasConcept C2777557582 @default.
• W2953184800 hasConcept C2778205648 @default.
• W2953184800 hasConcept C2780868729 @default.
• W2953184800 hasConcept C2908647359 @default.
• W2953184800 hasConcept C2991741193 @default.
• W2953184800 hasConcept C71924100 @default.
• W2953184800 hasConcept C99454951 @default.
• W2953184800 hasConceptScore W2953184800C111113717 @default.
• W2953184800 hasConceptScore W2953184800C112705442 @default.
• W2953184800 hasConceptScore W2953184800C121608353 @default.
• W2953184800 hasConceptScore W2953184800C126322002 @default.
• W2953184800 hasConceptScore W2953184800C141071460 @default.
• W2953184800 hasConceptScore W2953184800C187212893 @default.
• W2953184800 hasConceptScore W2953184800C2776884760 @default.
• W2953184800 hasConceptScore W2953184800C2777557582 @default.
• W2953184800 hasConceptScore W2953184800C2778205648 @default.
• W2953184800 hasConceptScore W2953184800C2780868729 @default.
• W2953184800 hasConceptScore W2953184800C2908647359 @default.
• W2953184800 hasConceptScore W2953184800C2991741193 @default.
• W2953184800 hasConceptScore W2953184800C71924100 @default.
• W2953184800 hasConceptScore W2953184800C99454951 @default.
• W2953184800 hasIssue "S1" @default.
• W2953184800 hasLocation W29531848001 @default.
• W2953184800 hasLocation W29531848002 @default.
• W2953184800 hasOpenAccess W2953184800 @default.
• W2953184800 hasPrimaryLocation W29531848001 @default.
• W2953184800 hasRelatedWork W2019564899 @default.
• W2953184800 hasRelatedWork W2048468205 @default.
• W2953184800 hasRelatedWork W2070380600 @default.
• W2953184800 hasRelatedWork W2166919504 @default.
• W2953184800 hasRelatedWork W2414467904 @default.
• W2953184800 hasRelatedWork W2414615566 @default.
• W2953184800 hasRelatedWork W2417026009 @default.
• W2953184800 hasRelatedWork W2466616124 @default.
• W2953184800 hasRelatedWork W2568229981 @default.
• W2953184800 hasRelatedWork W2735322539 @default.
• W2953184800 hasVolume "3" @default.
• W2953184800 isParatext "false" @default.
• W2953184800 isRetracted "false" @default.
• W2953184800 magId "2953184800" @default.
• W2953184800 workType "article" @default.